AnaptysBio, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ANAB, updated each market day.
ANAB AI Sentiment
AI predicts AnaptysBio, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About AnaptysBio, Inc. Common Stock
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Sector
Exchange
Market Cap
$1,970,405,397
Cap Tier
Employees
104
Headquarters
SAN DIEGO, CA
Listed Since
Jan. 26, 2017
Website
ANAB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ANAB Volatility
AnaptysBio, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
